Jun 3 |
Top Stock Reports for NextEra Energy, BP & Gilead Sciences
|
Jun 3 |
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
|
Jun 3 |
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
|
Jun 2 |
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
|
Jun 1 |
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
|
May 31 |
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
|
May 31 |
Gilead's Trodelvy falls short in significantly improving overall survival in NSCLC
|
May 31 |
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
|
May 31 |
Gilead’s Trodelvy misses goal in bladder cancer study
|
May 31 |
Gilead’s Phase III urothelial cancer trial fails to meet primary endpoint
|